Novel Augmentation of DAOIB and Antioxidant for Early Dementia

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Alzheimer Disease, Mild Cognitive Impairment

In brief

Previous studies found that some NMDA-enhancing agents were able to improve cognitive function of patients with early-phase dementia. In addition, several drugs with antioxidant properties have been tested in clinical trials for the treatment of dementia too. Whether combined treatment of an NMDA-enhancing agent and a drug with antioxidant property can be better than an NMDA-enhancing agent alone deserves study.

Key facts

Study ID

NCT06467539

Run by

Chang Gung Memorial Hospital

People needed

80

Starts

2024-06-19

Expected to finish

2027-05-01

Last updated by the study team

2026-03-19

Who can join

Age: 50 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis of Alzheimer's disease or mild cognitive impairment
• MMSE between 10-26
• CDR 1 or 0.5

You may not qualify if…

• Hachinski Ischemic Score > 4
• Substance abuse/dependence
• Parkinson disease, epilepsy, dementia with psychotic features
• Major depressive disorder
• Major physical illnesses
• Severe visual or hearing impairment

Where it is running

• Chang Gung Memorial Hospital — Kaohsiung City, Taiwan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.